Based on in vitro screening assays, neratinib and its metabolites are not expected to have off- target activity for other receptors, enzymes, or ion channels at clinically relevant concentrations.
Based on in vitro screening assays, neratinib and its metabolites are not expected to have off- target activity for other receptors, enzymes, or ion channels at clinically relevant concentrations.